ArticleTrials2024

A proof of concept phase II study with the PDE-4 inhibitor roflumilast in patients with mild cognitive impairment or mild Alzheimer's disease dementia (ROMEMA): study protocol of a double-blind, randomized, placebo-controlled, between-subjects trial.

Nina Possemis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.